Вопросы современной педиатрии (Nov 2012)

EFFICACY OF ETANERCEPT TREATMENT AS A SECOND TNF α INHIBITOR IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AND PRIMARY AND SECONDARY INEFFICIENCY OR INTOLERANCE OF INFLIXIMAB

  • E. I. Alexeeva,
  • T. M. Bzarova,
  • A. N. Fetisova,
  • T. V. Sleptsova,
  • K. B. Isaeva,
  • S. I. Valieva,
  • R. V. Denisova,
  • E. V. Mitenko,
  • E. G. Chistyakova

DOI
https://doi.org/10.15690/vsp.v11i6.490
Journal volume & issue
Vol. 11, no. 6
pp. 32 – 41

Abstract

Read online

The aim of the study was to assess the efficacy and safety of etanercept treatment in combination with methotrexate in 32 patients with juvenile idiopathic arthritis and primary and secondary inefficiency of intolerance of infliximab. In 1 month after the switching to etanercept the improvement was achieved in 84% of patients, 50% improvement — in 66%, 70% — in 55% according to the ACRpedi criteria. In 6 months of treatment non-active stage was registered in all the patients. Remission stage was established in 85% of children in 9 months, in all the patients — in 12 months. Etanercept was well-tolerated and the majority of side-effects were mild or moderate, reversible and did not interfere the treatment.

Keywords